Eli Lilly And Co (NYSE:LLY) reported on Thursday second-quarter revenue of $11.3 billion, up 36% year-over-year, easily surpassing the consensus of $9.95 billion. Mounjaro sales tripled to $3.09 billion from $979.7 million a year ago. Zepbound sales reached $1.24 billion, up from $517.4 million reported in the first quarter of 2024 since it received FDA approval in November 2023. Goldman Sachs noted that Eli Lilly’s second-quarter performance benefited from better channel dynamics and clearer manufacturing processes. However, they warned that rising demand might lead to occasional supply shortages for specific presentations and dose levels. “The guidance raise is impressive,” the analyst Chris Shibutani adds, raising the price target to $856 from $812. The analyst maintains a Neutral rating as Goldman Sachs is closely watching the narrowing supply/demand gap, which reassures them about execution but raises questions about the total addressable market (TAM), competitor ...